Annual General Meeting of Active Biotech AB
(Thomson Reuters ONE) -
PRESS RELEASE
The Annual General Meeting of Active Biotech was held on June 15, 2017.
In accordance with the Board of Directors' proposal, it was resolved that no
dividend would be paid.
The board members and the managing director were discharged from liability with
respect to their management of the company for 2016.
In accordance with the Election Committee's proposal, the Board members Mats
Arnhög, Magnhild Sandberg-Wollheim, Peter Sjöstrand and Peter Thelin were re-
elected. The Meeting also resolved to re-elect Mats Arnhög as Chairman of the
Board. KPMG AB was re-elected as auditor.
Furthermore, in accordance with the Election Committee's proposal, the Meeting
resolved that the Election Committee shall be composed of representatives for
the three largest owners, as per the end of September, 2017, as well as the
Chairman of the Board.
The Meeting approved the Board's proposal concerning guidelines for remuneration
to the President and other senior executives. The guidelines essentially conform
to the principles applied to date.
In accordance with the Board's proposal, the Meeting resolved to authorize the
Board, for a period that does not extend past the date of the next Annual
General Meeting, to resolve on the issue of not more than nine million new
shares and/or convertibles with the corresponding dilution effect, with or
without pre-emptive rights for the company's shareholders.
In accordance with the Board's proposal, the Meeting resolved to reduce the
company's share capital by approximately SEK 364,464,039 for allocation to
unrestricted shareholders' equity, without cancellation of shares, and to reduce
the statutory reserve by approximately SEK 118,870,784, for allocation to
unrestricted shareholders' equity. In addition thereto, the Meeting resolved to
amend the articles of association as proposed by the Board.
Lund, June 16, 2017
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
For further information, please contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/ inflammatory diseases and cancer. Laquinimod,
an orally administered small molecule with unique immunomodulatory properties,
is in Phase 2 development for the treatment of primary progressive multiple
sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in
clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal
cancer. Furthermore, commercial activities are conducted for the tasquinimod,
paquinimod and SILC projects. Please visit www.activebiotech.com for more
information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Annual General Meeting of Active Biotech AB:
http://hugin.info/1002/R/2113226/803868.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 16.06.2017 - 08:30 Uhr
Sprache: Deutsch
News-ID 548293
Anzahl Zeichen: 3681
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Annual General Meeting of Active Biotech AB"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
